

Treatment of Rat Adjuvant Arthritis with Flavonoid (Detralex[®]), Methotrexate, and Their Combination

Jozef Rovenský,^a Mária Stančíková,^a Emília Rovenská,^a Svetoslav Štvrtina,^b Viera Štvrtinová,^c and Karol Švík^a

^aNational Institute of Rheumatic Diseases, Piešťany, Slovak Republic

^bDepartment of Pathology, Medical Faculty of Comenius University, Bratislava, Slovak Republic

^c2nd Clinic of Internal Medicine, Medical Faculty of Comenius University, Bratislava, Slovak Republic

In both adjuvant arthritis and rheumatoid arthritis, edema and inflammation appear in synovial joints. Edema or effusion reflects an imbalance in lymph dynamics. Purified micronized flavonoid fraction is mainly used in the treatment of chronic venous insufficiency. This compound improves lymphatic drainage with a significant increase in lymphatic flow and lymphatic pulsatility. It is suggested that the beneficial effect of purified micronized flavonoid fraction may be involved in the treatment of adjuvant arthritis in rats. In this study treatment of adjuvant arthritis in rats with Detralex, methotrexate, and their combination were evaluated. Groups of rats with adjuvant arthritis were treated with methotrexate (0.6 mg/kg/week), Detralex (20 mg/kg/day), and their combination for 50 days from adjuvant application. Hind paw swelling, arthrograph scores, serum albumin level, serum nitrite/nitrate concentrations, and whole-body mineral density were evaluated as markers of inflammation and destructive changes associated with arthritis. Long-term prophylactic treatment with low-dose methotrexate significantly inhibited the markers of both inflammation and arthritis. Detralex administered alone slightly decreased both the hind paw swelling and the arthritic score. Other inflammatory and arthritic markers were not significantly influenced. However, Detralex combined with methotrexate markedly potentiated the beneficial effects of methotrexate, which resulted in a more significant reduction in hind paw swelling, arthritic scores, and serum concentrations of nitrite/nitrate. Interestingly, the arthritis-induced decrease of bone mineral density in AA rats was significantly lower only in the group treated with the combination of Detralex and methotrexate. Our results indicate that Detralex increased the therapeutic efficacy of methotrexate basal treatment in AA. We suggest that this may be related to the beneficial effect of Detralex on microcirculation, especially on venules and lymphatic vessels.

Key words: purified micronized flavonoid fraction; Detralex; methotrexate; adjuvant arthritis; microcirculation

Detralex[®] (Les Laboratoires Servier, France), a purified micronized flavonoid fraction, contains two flavonoids: diosmin (90%)

and hesperidine (10%). Micronized flavonoid fraction is also known under other names: 5682 SE, daflon 500, arvenum 500, capiven, or venotec. Daflon 500, like the majority of flavons, has antioxidant properties; it is an effective scavenger of reactive oxygen species *in vitro* and *in vivo*.¹ *In vitro* daflon 500 inhibits both classic and alternative pathways of complement

Address for correspondence: Prof. MUDr. J. Rovenský, DrSc, FRCP, National Institute of Rheumatic Diseases, Nábřežie I. Krasku 4, 921 12 Piešťany, Slovak Republic. Voice: 00421337723586; fax: 00421337721192. rovensky@nurch.sk

activation.² Activation of the complement system during the early phase of inflammation is partially responsible for increased capillary permeability.

Purified micronized flavonoid fraction is mainly used in the treatment of chronic venous insufficiency. The beneficial venotropic effect of daflon 500 on blood vessels in patients with chronic venous insufficiency was proven by clinical evaluations and intravital capillaroscopy.³⁻⁵ The results of experimental studies in dogs and rats have shown that daflon 500 improves lymphatic drainage,^{4,6} with a significant increase in lymphatic flow and lymphatic pulsatility.^{6,7} Micronized flavonoid fraction also significantly decreased the migration of leukocytes from postcapillary venules to the surrounding connective tissue during an experimentally induced venous occlusion and subsequent reperfusion.^{8,9} A generalized abnormality in capillary function (an increase in capillary filtration rate) and some obstruction of lymphatic clearance are associated with rheumatoid arthritis.^{10,11} Microscopic changes of postcapillary venules were also found in RA,^{12,13} and structural changes of lymphatic vessels in synovial membrane were observed in RA and juvenile idiopathic arthritis.¹⁴⁻¹⁶

Adjuvant arthritis, an experimentally induced inflammatory disorder in rats, bears some features of rheumatoid arthritis. In both diseases edema and inflammation appear in synovial joints. Edema or effusion reflects an imbalance in lymph dynamics.¹⁷ The animal model of AA is widely used for testing drugs with anti-inflammatory and anti-arthritic effects. The aim of the present study was to evaluate the effect of Detralex on clinical symptoms and certain laboratory markers of AA during basal treatment with methotrexate.

Methods

Materials

Methotrexate was purchased as pure substance from Pliva-Lachema Ltd., Brno (Czech

Republic). Detralex was obtained from Les Laboratoires Servier (France). *Mycobacterium* in lyophilized form was purchased from Difco Laboratories Co. Ltd. (Detroit, MI, USA) and incomplete Freund's adjuvant from Sigma-Aldrich Chemie GmbH (Taufkirchen, Germany).

Animals

Male Lewis rats (170 ± 10 g; Sulzfeld, Germany) were maintained during the experiment in standard animal facilities that comply with requirements of the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes. The animals were fed pelleted food (TOP DOVO, Slovak Republic) and had free access to food and water. The State Veterinary and Food Committee of the Slovak Republic and the Ethics Committee for Control of Animal Experimentation of the National Institute of Rheumatic Diseases approved the experimental protocol and all procedures.

Induction of Arthritis

The rats were injected with 0.1 ml suspension of heat-killed *Mycobacterium butyricum* (12 mg/ml) in incomplete Freund's adjuvant. The injection was administered intradermally at the base of the tail.

Treatment

Tested substances were administered in corresponding doses from day 0 (the day of immunization) to day 50 of the study. Detralex 20 mg/kg in the form of fine suspension in saline was administered daily *per os*. Methotrexate was prepared in sterile saline to yield the desired concentration of 0.3 mg/kg in 0.1 ml saline, and applied twice a week *per os* (0.6 mg/kg in total per week). Fresh solutions of the tested substances were prepared each day of administration. The untreated AA group received the vehicle (sterile saline) in the same manner daily for 50 days.

Rat Groups

The animals were divided into five groups of eight animals: group 1: nonarthritic untreated healthy controls; group 2: untreated rats with AA; group 3: AA rats treated with methotrexate; group 4: AA rats treated with Detralex; group 5: AA rats treated with the combination of methotrexate and Detralex.

Evaluated Parameters

Hind Paw Swelling

The volume of hind paw swelling was measured with an electronic water plethysmometer (UGO BASILE, Italy) on days 14, 21, and 28.

Arthrogram Score

The severity of arthritis was quantified by scoring each paw from 1 to 5, based on increasing levels of swelling and periarticular erythema. The sum of the scores for the limbs was calculated as the arthritic index, with a maximum possible score of 20 per rat. Arthrogram scores were evaluated on days 14, 21, and 28.

Serum Albumin

Serum albumin was measured on days 14, 21, and 28 in the rat serum by the spectrophotometric method using SYS 1 kit (BM/Hitachi, Boehringer Mannheim, Germany) on a Hitachi 911 automatic biochemical analyzer.

Serum Nitrite/Nitrate

Nitrite/nitrate concentration in deproteinized serum was determined by the method of Cortas and Waking¹⁸ on days 14, 21, and 28. Cu-coated cadmium granules in glycine buffer at pH 9.7 reduced nitrate to nitrite. The total nitrite concentrations were determined by the Griess reaction.

Bone Mineral Density (BMD)

BMD was measured by dual-energy X-ray absorptiometry using Hologic QDR[®]-4500 (Waldham, MA, USA) with the equipment for measuring small laboratory animals. The

whole body BMD of rats was determined on day 50 after immunization.

Statistical Analysis of the Results

One-way analysis of variance (ANOVA) was used for statistical analysis of the results, and $P < 0.05$ was considered as the significance limit for all comparisons.

Results

Hind Paw Swelling and Arthrogram Score

These markers reflect both inflammatory and arthritic changes occurring in rats with AA. The volume of the swollen hind paws in arthritic rats on day 21 was about twice that found in healthy controls (Table 1). A statistically significant decrease of both hind paw swelling and arthrogram scores were observed in rats treated with methotrexate compared to untreated arthritic controls. The reductions in both hind paw swelling and arthrogram scores were more pronounced in rats treated with the combination of methotrexate and Detralex than in those treated with methotrexate alone (Tables 1 and 2). Detralex alone tended to reduce both these markers, but the decrease was not statistically significant in comparison with untreated AA rats.

Serum Albumin

Serum albumin acts as a negative acute phase reactant in both rat and human arthritis. Lower levels of serum albumin correspond to higher levels of inflammatory activity. The concentration of albumin in the serum of arthritic controls was significantly lower than in healthy controls (nonarthritic untreated controls vs. AA rats, $P < 0.001$). Both methotrexate and the combination of Detralex and methotrexate significantly inhibited the decrease in serum

TABLE 1. The Effects of Methotrexate (MTX), Detralex (DTX), and Their Combination on Hind Paw Edema (ml) and on Whole-Body Bone Mineral Density (BMD; g/cm²) in AA Rats

	Day 14	Day 21	Day 28	BMD, Day 50
Healthy Controls	1.34 ± 0.07***	1.41 ± 0.05***	1.41 ± 0.02***	0.1382 ± 0.0087***
AA Controls	2.05 ± 0.29	2.46 ± 0.33	2.34 ± 0.27	0.1222 ± 0.0046
AA Rats Treated with				
MTX	1.59 ± 0.06***	1.85 ± 0.27**	1.83 ± 0.26*	0.1259 ± 0.0050
DTX	1.86 ± 0.31	2.28 ± 0.26	2.17 ± 0.22	0.1206 ± 0.0046
DTX and MTX	1.48 ± 0.25***	1.71 ± 0.35***	1.77 ± 0.30**	0.1275 ± 0.0051*

Data represent mean values ± SD $N = 8$ rats.

Significantly different from arthritic control rats: * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

albumin (Table 3). Detralex without methotrexate did not influence this inflammatory marker.

Serum Nitrite/Nitrate

Serum concentrations of nitrite/nitrate reflect nitric oxide production in various tissues during inflammation. The clinical onset of AA was associated with a significant rise in nitrite/nitrate concentrations. Methotrexate alone and in combination with Detralex significantly decreased nitrite/nitrate concentrations compared to AA controls (Table 4). Detralex had no significant effect on the serum nitrite/nitrate concentrations, however it did potentiate the beneficial effect of methotrexate during the whole experiment, which resulted in a more significant reduction of nitrite/nitrate concentrations in rats treated with the combination of methotrexate and Detralex compared to methotrexate administered alone ($P < 0.01$ vs. $P < 0.05$) (Table 4).

Whole-Body BMD

The development of arthritis in both humans and rats is associated with the development of osteopenia due to the activation of pro-inflammatory cytokines. At the end of the study (day 50) AA rats had markedly lower values of whole body BMD compared to healthy controls (Table 1). Evaluation of different treatments showed that only the combination of methotrexate and Detralex significantly inhibited the whole body BMD decrease in AA rats.

Discussion

This experiment focused on the effect of Detralex on the inflammatory and arthritic markers in rats with AA during basal treatment with methotrexate. The treatment was prophylactic, which means that the animals were treated immediately after administration of the adjuvant. Since the effect on BMD was also investigated, the duration of the treatment was longer

TABLE 2. The Effects of Methotrexate (MTX), Detralex (DTX), and Their Combination on the Arthrograph Score in AA Rats

	Day 14	Day 21	Day 28
AA Controls	15.33 ± 3.12	18.22 ± 1.66	17.00 ± 1.83
AA Rats Treated with			
MTX	8.80 ± 1.87***	12.70 ± 2.98***	13.60 ± 3.86**
DTX	13.60 ± 3.86	18.00 ± 2.87	19.10 ± 2.23
DTX and MTX	6.90 ± 4.58***	10.80 ± 4.08***	12.10 ± 3.96***

Data represent mean values ± SD $N = 8$ rats.

Significantly different from arthritic control rats: ** $P < 0.01$, *** $P < 0.001$.

TABLE 3. The Effects of Methotrexate (MTX), Detralex (DTX), and Their Combination on Serum Albumin Concentrations (g/L) in AA Rats

	Day 14	Day 21	Day 28
Healthy Controls	42.53 ± 2.04***	42.34 ± 2.03***	43.80 ± 2.39***
AA Controls	29.01 ± 1.75	31.23 ± 1.07	33.44 ± 1.76
AA Rats Treated with			
MTX	32.25 ± 3.46*	33.38 ± 2.56*	35.21 ± 1.25*
DTX	28.83 ± 1.07	29.58 ± 1.28	31.51 ± 1.93
DTX and MTX	31.55 ± 2.25*	33.79 ± 2.78*	35.50 ± 1.61*

Data represent mean values ± SD $N = 8$ rats.

Significantly different from arthritic control rats: * $P < 0.05$, *** $P < 0.001$.

(50 days) than usual (10–14 days) to prevent exacerbation of arthritis after discontinuation of the therapy.

The results of our study confirmed observations on methotrexate treatment reported by Welles et al.¹⁹ and Connolly et al.²⁰ Methotrexate at a dose of 0.6 mg/kg/week suppressed but did not prevent the development of arthritis. In our study, it significantly suppressed the hind paw swelling and decreased the arthrograph scores. Detralex alone tended to decrease these parameters, but the decrease was not statistically significant compared to the group of untreated AA rats. The remarkable finding was that Detralex potentiated the beneficial effect of methotrexate; reductions in hind paw swelling and arthrograph scores on days 21 and 28 were more significant compared to rats treated with methotrexate alone (Tables 1 and 2). We presume that Detralex might influence permeability of tiny blood vessels and improve lymphatic drainage of joints

affected by synovitis. Several authors reported the beneficial effect of micronized flavonoid fraction on blood and lymphatic vessels in humans, dogs and rats.^{3–8} They also found a significant increase in the lymphatic flow and pulsatile activity of lymphatic vessels after daflon 500 application in dogs and rats.^{6,7}

Serum albumin acts as a negative acute-phase reactant in rat arthritis, and the decrease in serum albumin levels reflects the changes in synthesis of this protein in the liver secondary to the activation of hepatic cells by inflammatory cytokines, mainly interleukin-1.²⁰ Our results (Table 3) correlate with the observation that methotrexate markedly prevents the albumin decrease in AA rats.²⁰ The administration of Detralex alone or in combination had no effect on this parameter (Table 3).

Nitric oxide, an unstable free radical produced by the action of the enzyme NO synthase on L-arginine, is a mediator of multiple physiological functions, and may also

TABLE 4. The Effects of Methotrexate (MTX), Detralex (DTX), and Their Combination on Serum Nitrites/Nitrates Concentrations (nmol/ml) in AA Rats

	Day 14	Day 21	Day 28
Healthy Controls	25.07 ± 5.82***	29.44 ± 7.68***	32.58 ± 7.01***
AA Controls	108.80 ± 26.15	78.25 ± 10.89	69.97 ± 11.63
AA Rats Treated with			
MTX	84.12 ± 19.87*	62.63 ± 16.00*	59.65 ± 9.92*
DTX	100.55 ± 29.79	90.78 ± 17.26	75.07 ± 11.56
DTX and MTX	68.57 ± 19.52**	59.48 ± 9.18**	57.52 ± 4.35**

Data represent mean values ± SD $N = 8$ rats.

Significantly different from arthritic control rats: * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

mediate local inflammation and tissue destruction.²¹ Nitric oxide is involved in both initiation and development of AA in rats.²² Moreover, inhibitors of NOS have been shown to suppress arthritis in several animal models,^{23,24} and increased NO levels have been found in patients with rheumatoid arthritis.^{25,26} Omata and co-workers²⁷ reported that methotrexate suppresses *ex vivo* production of NO in macrophages of rats with AA. In our study, markedly increased serum nitrite/nitrate concentrations were found in AA rats. Flavonoid hesperidine (component of Detralex) markedly decreases the formation of inducible NOS in liposaccharide-activated macrophages *in vitro* at the level of NOS gene transcription.²⁸ We presume that hesperidine largely contributes to reducing serum nitrite/nitrate level in AA rats treated with the combination of Detralex and methotrexate also in our experiment (Table 4).

Marked osteopenia and extensive bone loss have been described in AA rats.²⁹ Suzuki et al.³⁰ reported that low-dose weekly methotrexate therapy had a favorable effect on abnormal bone metabolism and osteopenia in rats with AA. In our study, methotrexate (0.6 mg/kg/week) alone had no effect on whole body BMD in rats. However, in our experiment the combination of methotrexate with Detralex significantly reduced the BMD loss in AA rats compared to the group treated with methotrexate only. We suggest that this may be due to the effect of the combination treatment on microcirculation in bone tissue. Administration of Detralex alone had no such effect.

Recently, flavonoid hesperidine was used to treat collagen-induced arthritis in mice.³¹ The authors found a significant reduction in the clinical parameters and an improvement in the histological picture of the disease in arthritic mice treated with hesperidine. Shevchuk et al.³² used Detralex to treat patients with RA and found an increased therapeutic effect of methotrexate and decrease in the adverse effects of methotrexate.

In conclusion, our results demonstrate that Detralex does not cause any worsening of the

parameters evaluated; on the contrary, it mildly reduces some of the clinical symptoms of AA such as hind paw edema and arthritic score. Our findings showed that Detralex increased the efficacy of basal methotrexate therapy in AA rats. Furthermore, our study suggests that this may be related to the beneficial effect of Detralex on microcirculation, especially on venules and lymphatic vessels.

Conflicts of Interest

The authors declare no conflicts of interest.

References

- Lonchamp, M., B. Guardiola, *et al.* 1989. Protective effect of a purified flavonoid fraction against reactive oxygen radicals. In vivo and in vitro study. *Arzneimittelforschung* **39**: 882–885.
- Di Perri, T. & A. Auteri. 1988. Action of S 5682 on the complement system. In vitro and in vivo study. *Int. Angiol.* **7**(Suppl 2): 11–15.
- Laurent, R., R. Gilly & C. Frileux. 1988. Clinical evaluation of a venotropic drug in man. *Int. Angiol.* **7**(Suppl 2): 39–43.
- Földi, M. 1999. *Atlas of the Lymphatics of the Lower Limbs*, pp. s1–80. Les Laboratoires Servier. Paris.
- Bollinger, A., I. Herrig, *et al.* 1995. Intravital capillaroscopy in patients with chronic venous insufficiency and lymphoedema: relevance to Daflon 500 mg. *Int. J. Microcirc. Clin. Exp.* **15**(Suppl 1): 41–44.
- Labrid, C. 1995. A lymphatic function of Daflon 500. *Int. Angiol.* **14**(Suppl 1): 36–38.
- Cotonat, A. & J. Cotonat. 1989. Lymphagogue and pulsatile activities of Daflon 500 on canine thoracic lymph duct. *Int. Angiol.* **8**(Suppl 4): 15–18.
- Takase, S., F.A. Delano, *et al.* 1999. Inflammation in chronic venous insufficiency. Is the problem insurmountable? *J. Vasc. Res.* **36**(Suppl 1): 3–10.
- Friesenecker, B., A.G. Tsai, *et al.* 1994. Oral administration of purified micronized flavonoid fraction suppresses leukocyte adhesion in ischemia-reperfusion injury: in vivo observations in the hamster skin fold. *Int. J. Microcirc.* **14**: 50–55.
- Jayson, M.I.V. & J.S. Barks. 1971. Oedema in rheumatoid arthritis: changes in the coefficient of capillary filtration. *Br. Med. J.* **2**: 555–557.
- Jayson, M.I.V., I. Cavill & J.S. Barks. 1971. Lymphatic clearance rates in rheumatoid arthritis. *Ann. Rheum. Dis.* **30**: 638–639.

12. Freemont, A., C.J.P. Jones, *et al.* 1983. Changes in vascular endothelium related to lymphocyte collections in diseased synovia. *Arthritis Rheum.* **26**: 1427–1443.
13. Schumacher, H.R. & R.C. Kitridou. 1972. Synovitis of recent onset. A clinicopathologic study during the first month of disease. *Arthritis Rheum.* **15**: 465–485.
14. Rovenská, E., E. Rovenská & J. Neumüller. 2003. Structure of synovial lymphatic capillaries in rheumatoid arthritis and juvenile idiopathic arthritis. *Int. J. Tissue React.* **25**: 29–38.
15. Xu, H., J. Edwards, *et al.* 2003. Distribution of lymphatic vessels in normal and arthritic human synovial tissues. *Ann. Rheum. Dis.* **62**: 1227–1229.
16. Rovenská, E., S. Štvrtina, *et al.* 2005. Conspicuous synovial lymphatic capillaries in juvenile idiopathic arthritis synovitis with rice bodies. *Ann. Rheum. Dis.* **64**: 328–329.
17. Witte, Ch., M.H. Witte & A.E. Dumont. 1984. Pathophysiology of chronic edema, lymphedema, and fibrosis. In *Edema*. N.C. Staub & A.E. Taylor, Eds.: 521–542. Raven Press. New York, NY.
18. Cortas, N.K. & N.W. Waking. 1990. Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. *Clin. Chem.* **36**: 1440–1443.
19. Welles, W.L., J. Silkworth, *et al.* 1985. Studies on the effect of low dose methotrexate in adjuvant arthritis. *J. Rheumatol.* **12**: 904–906.
20. Connolly, K.M., V.J. Stecher, *et al.* 1988. Alteration of interleukin-1 production and the acute phase response following medication of adjuvant arthritic rats with cyclosporin-A or methotrexate. *Int. J. Immunopharmacol.* **10**: 717–728.
21. Stamler, J.S., D.J. Singel & J. Loscalzo. 1992. Biochemistry of nitric oxide and its redox-activated forms. *Science* **258**: 1898–1902.
22. Oyanagui, Y. 1994. Nitric oxide and superoxide radical are involved in both initiation and development of adjuvant arthritis in rats. *Life Sci.* **54**: PL285–289.
23. Cannon, G.W., S.J. Openshaw, *et al.* 1996. Nitric oxide production during adjuvant-induced and collagen induced arthritis. *Arthritis Rheum.* **39**: 1677–1684.
24. Stefanovic-Racic, M., K. Meyers, *et al.* 1995. Comparison of the nitric oxide synthase inhibitors methylarginine and aminoguanidine as prophylactic and therapeutic agents in rat adjuvant arthritis. *J. Rheumatol.* **22**: 1992–1998.
25. Grabowski, P.S., A.J. England, *et al.* 1996. Elevated nitric oxide production in rheumatoid arthritis: detection using the fasting urinary nitrate:creatinine ratio. *Arthritis Rheum.* **39**: 643–647.
26. Ueki, Y., S. Miyake, *et al.* 1996. Increased nitric oxide levels in patients with rheumatoid arthritis. *J. Rheumatol.* **23**: 230–236.
27. Omata, T., Y. Segawa, *et al.* 1997. Methotrexate suppresses nitric oxide production ex vivo in macrophages from rats with adjuvant-induced arthritis. *Res. Exp. Med.* **197**: 81–90.
28. Olszanecki, R., A. Gebaska, *et al.* 2002. Flavonoids and nitric oxide synthase. *J. Physiol. Pharmacol.* **53**: 571–584.
29. Bonnet, J., E. Zerath, *et al.* 1993. Bone morphometric changes in adjuvant-induced polyarthritic osteopenia in rats: evidence for an early bone formation defect. *J. Bone Miner. Res.* **8**: 659–668.
30. Suzuki, Y., M. Nakagawa, *et al.* 1997. Short term low dose methotrexate ameliorates abnormal bone metabolism and bone loss in adjuvant induced arthritis. *J. Rheumatol.* **24**: 1890–1895.
31. Kawaguchi, K., H. Maruyama, *et al.* 2006. Suppression of collagen-induced arthritis by oral administration of the citrus flavonoid hesperidin. *Planta Med.* **72**: 477–479.
32. Shevchuk, S.V., M.A. Stanislavchuk & O.O. Pentiu. 2003. Efficacy and safety of treatment with methotrexate, leflunomide, detralex, and their combination of patients with rheumatoid arthritis. *Lik. Sprava.* **3–4**: 34–41.